These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 13330188)

  • 1. In vivo fibrinolytic activity and pharmacology of various plasmin (fibrinolysin) preparations.
    BACK N; AMBRUS JL; GOLDSTEIN S; HARRISSON JW
    Circ Res; 1956 Jul; 4(4):440-3. PubMed ID: 13330188
    [No Abstract]   [Full Text] [Related]  

  • 2. Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme.
    AMBRUS CM; MARKUS G
    Am J Physiol; 1960 Sep; 199():491-4. PubMed ID: 13682944
    [No Abstract]   [Full Text] [Related]  

  • 3. Fibrinolytic (plasmin) therapy of experimental coronary thrombi with alteration of the evolution of myocardial infarction.
    RUEGSEGGER P; NYDICK I; HUTTER RC; FREIMAN AH; BANG NU; CLIFFTON EE; LADUE JS
    Circulation; 1959 Jan; 19(1):7-13. PubMed ID: 13619015
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of human fibrinolysin (actase); lack of fibrinolytic activity after intravenous administration in man.
    FLETCHER AP; ALKJAERSIG N; SAWYER WD; SHERRY S
    J Am Med Assoc; 1960 Feb; 172():912-5. PubMed ID: 13823474
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis.
    Morris TA; Marsh JJ; Chiles PG; Auger WR; Fedullo PF; Woods VL
    Am J Respir Crit Care Med; 2006 Jun; 173(11):1270-5. PubMed ID: 16514114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of heparin and a covalently-linked antithrombin-heparin complex with components of the fibrinolytic system.
    Chander A; Atkinson HM; Stevic I; Berry LR; Kim PY; Chan AK
    Thromb Haemost; 2013 Dec; 110(6):1180-8. PubMed ID: 24048327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of plasmin in marginal donor lungs in an ex vivo lung perfusion model.
    Motoyama H; Chen F; Ohsumi A; Hijiya K; Okita K; Nakajima D; Sakamoto J; Yamada T; Sato M; Aoyama A; Bando T; Date H
    J Heart Lung Transplant; 2013 May; 32(5):505-10. PubMed ID: 23499355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action of fibrinolysin (plasmin) on proteins.
    KAPLAN EH
    Proc Soc Exp Biol Med; 1954 Jan; 85(1):142-4. PubMed ID: 13134315
    [No Abstract]   [Full Text] [Related]  

  • 10. Variations in serum lipids with fibrinolytic and proteolytic activity in dogs and rabbits.
    BANG NU; CLIFFTON EE
    Am J Physiol; 1961 Feb; 200():323-6. PubMed ID: 13686573
    [No Abstract]   [Full Text] [Related]  

  • 11. FIBRIN SUSPENSION ASSAY FOR FIBRINOLYTIC ACTIVITY.
    DYER AE; KADAR D
    Blood; 1964 Jun; 23():729-40. PubMed ID: 14161407
    [No Abstract]   [Full Text] [Related]  

  • 12. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
    Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
    Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasmin heavy chain-urokinase conjugate: a specific thrombolytic agent.
    Nakayama Y; Shinohara M; Tani T; Kawaguchi T; Furuta T; Izawa T; Kaise H; Miyazaki W; Nakano Y
    Thromb Haemost; 1986 Dec; 56(3):364-70. PubMed ID: 2951892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [On the vasodilating and fibrinolytic action of nicotinic acid in the therapy of pregnancy toxicoses].
    CARLI R
    Quad Clin Ostet Ginecol; 1960 Apr; 15():237-46. PubMed ID: 13807725
    [No Abstract]   [Full Text] [Related]  

  • 15. [A method for determining plasmin by the rate of fibrin gel lysis].
    Popova GIu; Eremeev NL; Aĭsina RB; Kazanskaia NF
    Biull Eksp Biol Med; 1989 May; 107(5):561-4. PubMed ID: 2525408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-species pharmacologic evaluation of plasmin as a direct-acting thrombolytic agent: ex vivo evaluation for large animal model development.
    Landskroner K; Olson N; Jesmok G
    J Vasc Interv Radiol; 2005 Mar; 16(3):369-77. PubMed ID: 15758133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinolysis. V. The thrombolytic and anticoagulant activity of mold fibrinolysin (Aspergillin O) in vivo.
    MARIN HM; STEFANINI M; SOARDI F; MUELLER L
    J Lab Clin Med; 1961 Jul; 58():47-59. PubMed ID: 13766766
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.
    Hoffmeister HM; Kastner C; Szabo S; Beyer ME; Helber U; Kazmaier S; Baumbach A; Wendel HP; Heller W
    Am J Cardiol; 2000 Aug; 86(3):263-8. PubMed ID: 10922430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmin potency estimates: influence of the substrate used in assay.
    Philo RD; Gaffney PJ
    Thromb Haemost; 1981 Apr; 45(2):107-9. PubMed ID: 6454987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.